Utilization of orphan drugs in the U.S. from 2012 to 2014, by usage type

Percentage of annual utilization among select orphan drugs in the U.S. from 2012 to 2014, by usage type

CharacteristicOrphan useNon-orphan useOff-label use
Xiaflex 98.4% 0% 1.6%
Vpriv 98% 0% 2%
Kalydeco 97.2% 0% 2.8%
Ampyra 97.2% 0% 2.8%
Caprelsa 96.2% 0% 3.8%
Cayston 96% 0% 4%
Xalkori 95.9% 0% 4.1%
Velcade 95.6% 0% 4.4%
Jakafi 94% 0% 6%
Zelboraf 93.4% 0% 6.6%
Iclusig** 92.9% 0% 7.1%
Soliris 92.7% 0% 7.3%
Lumizyme*** 92.6% 0% 7.4%
Created with Highcharts 7.2.2Usage percentage98.4%98.4%98%98%97.2%97.2%97.2%97.2%96.2%96.2%96%96%95.9%95.9%95.6%95.6%94%94%93.4%93.4%92.9%92.9%92.7%92.7%92.6%92.6%90.4%90.4%84.5%84.5%83.8%83.8%83.5%83.5%82.3%82.3%81.1%81.1%78%78%74.8%74.8%64.1%64.1%62.8%62.8%62.6%62.6%54.9%54.9%54.3%54.3%43.9%43.9%43%43%42.1%42.1%37.5%37.5%34.9%34.9%23.1%23.1%22.6%22.6%19.8%19.8%12.5%12.5%9.3%9.3%7.8%7.8%4.5%4.5%3.2%3.2%2.2%2.2%1.9%1.9%1.8%1.8%1.1%1.1%0.3%0.3%0.1%0.1%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%10.3%10.3%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%21.9%21.9%0%0%57.3%57.3%63.6%63.6%52.9%52.9%74.9%74.9%66.7%66.7%72.7%72.7%18.1%18.1%93.2%93.2%0%0%96.6%96.6%90.2%90.2%0%0%33.4%33.4%61.9%61.9%90.5%90.5%1.6%1.6%2%2%2.8%2.8%2.8%2.8%3.8%3.8%4%4%4.1%4.1%4.4%4.4%6%6%6.6%6.6%7.1%7.1%7.3%7.3%7.4%7.4%9.6%9.6%5.2%5.2%16.2%16.2%16.5%16.5%17.7%17.7%18.9%18.9%22%22%25.2%25.2%35.9%35.9%37.2%37.2%37.4%37.4%45.1%45.1%45.7%45.7%56.1%56.1%57%57%36%36%62.5%62.5%7.8%7.8%13.3%13.3%24.5%24.5%5.2%5.2%20.8%20.8%18%18%74.1%74.1%2.3%2.3%96.8%96.8%1.2%1.2%7.9%7.9%98.2%98.2%65.6%65.6%37.8%37.8%9.5%9.5%Orphan useNon-orphan useOff-label useXiaflexVprivKalydecoAmpyraCaprelsaCaystonXalkoriVelcadeJakafiZelborafIclusig**SolirisLumizyme***MozobilPromactaNplateCinryzeTyvasoBerinertKalbitorFerriproxMakenaAdcircaFirazyrOnfiZirganBanzelXenazineSabrilCuvposaVotrientGleevecGamunexSensiparRituxanAfinitorAvastinRemicadeCoartemHerceptinHumiraGraliseHorizant*ColcrysViread
0%5%10%15%20%25%30%35%40%45%50%55%60%65%70%75%80%85%90%95%100%105%110%115%
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

October 2016

Region

United States

Survey time period

01 January 2012 to 31 December 2014

Supplementary notes

* The cumulative price change is based on changes in the unit price for NDC #00173-0806-01 & #53451-0101-01.
** As Iclusig was not approved by the FDA until December, 2012 it was included in the study; however, its pricing and utilization data were from 2013 to 2014 only.
*** Includes patients prescribed Myozyme.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Other statistics that may interest you

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

6

Other regions

10

Related statistics

10

Further related statistics

10
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Learn more about how Statista can support your business.